Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

ense. 

Total operating costs and expenses in the second quarter of 2014 were $51.4 million as compared to $66.5 million in the second quarter of 2013.  Total operating costs and expenses in the first half of 2014 were $107.6 million as compared to $134.6 million in the first half of 2013.  Total operating costs and expenses decreased primarily as a result of decreased research and development (R&D) expense, as well as decreased cost of goods sold associated with decreased manufacturing activity.

Research and development expense in the second quarter of 2014 was $36.7 million as compared to $52.2 million in the second quarter of 2013.  For the first half of 2014, R&D expense was $75.0 million as compared to $97.8 million in the first half of 2013.  R&D expense was lower in the second quarter and first half of 2014 as compared to the same periods in 2013 primarily because of reduced expenses for the Phase 3 study of etirinotecan pegol (NKTR-102) in metastatic breast cancer, which completed enrollment in the third quarter of 2013. Additionally, R&D expense in the second quarter and first half of 2013 included costs related to the Phase 2 study of NKTR-181, which was completed in 2013.  These decreases in R&D expense in 2014 were partially offset by costs for the preparation for the start of Phase 3 for NKTR-181, the ongoing Phase 1 study of NKTR-171, and the continued production of devices for the ongoing Phase 3 studies of Amikacin Inhale.

General and administrative expense was $9.6 million in the second quarter of 2014 as compared to $9.2 million in the second quarter of 2013.  G&A expense in the first half of 2014 was $19.5 million as compared to $20.1 million in the first half of 2013.

Non-cash interest expense incurred in connection with the 2012 royalty monetization was $5.1 million and $10.5 million in the second quarter and first half of 2014, respectively, as compared to $
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... DUBLIN , May 20, 2015 ... addition of the "Guide to Prepare Application ... in China (2014 Edition) " report to ... market is one of segment market of the ... more overseas medical device manufacturers and producers to ...
(Date:5/22/2015)... 22, 2015 Research and Markets ... the "Latest Regulations on Pharmaceutical International Multi-Center ... offering. This is first time in ... on international multi-center clinical trials of drugs in ... to be implemented on March 1, 2015. The ...
(Date:5/22/2015)... May 22, 2015  In a sweeping analysis assessing ... T1D Exchange researchers conclude that there remains ... diabetes across all age groups, but especially for adolescents ... picture of diabetes treatment, underscoring the need to address ... that can help type 1 patients achieve optimal metabolic ...
Breaking Medicine Technology:China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 32015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5
... OmniComm Systems, Inc. (OTC Bulletin Board: OMCM ... announced that it will be hosting the autumn eClinical ... in Fort Lauderdale, Florida from November 03-05, 2010. The ... Life Science organizations. The informal ambiance provides support for ...
... Calif., Sept. 21 Bionovo, Inc. (Nasdaq: BNVI, BNVID), a ... in women,s health and oncology, today announced that Dr. Isaac ... at the JMP Securities Healthcare Conference at 4:00 p.m. ET ... at the New York Palace hotel in New York City. ...
Cached Medicine Technology:OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 3Bionovo to Present at the JMP Securities Healthcare Conference 2
(Date:5/22/2015)... May 22, 2015 Family, friends, students, ... world-renowned surgical oncologist, Dr. LaSalle D. Leffall, on Monday, ... luncheon began after Grand Rounds in the hospital’s Tower ... anxiously outside the auditorium, trying to keep the secret. ... if he sees me, he’ll know something is up,” ...
(Date:5/22/2015)... 22, 2015 Power Systems is proud to ... 2015 race season. Drobeck is in his second year of ... firefighter with the Missoula Fire Department in Missoula, MT. He ... in 2014. During his career, he has had 15 1st ... recorded top 10 finishes in all seven of his 2014 ...
(Date:5/22/2015)... Gateway Building Concepts is experienced with all forms of ... in include decks, additions, kitchen remodeling, interior renovations, exterior ... , The redesigned logo is a fresh modern ... includes two geometrical lines that represent the engineering aspect ... used with many things associated with the company. The ...
(Date:5/22/2015)... May 22, 2015 DMG Productions announces ... scheduled to broadcast on Friday, May 29, 2015 at ... Channel. , In this episode Innovations will explore Interstate ... to business quickly through disaster recovery and restoration. , ... that works collaboratively to develop and deliver training and ...
(Date:5/22/2015)... Co founders Greenlee and James Chapko, DDS have ... to immediately deliver fully integrated dental implant services to their ... medical surgeon. , The Center, whose name is ... from placing dental implants. These 6 roadblocks can discourage ... surgical placement of dental implants into his or her practice. ...
Breaking Medicine News(10 mins):Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2Health News:First of Its Kind Dental Implant Training and Surgicenter to Open in June 2
... first time to date, research published in the October ... sought to determine the use of chemotherapy in ... encompassing all patient ages. Prior population-based studies have shown ... cancer patients receive chemotherapy treatment. These studies have previously ...
... Researchers from the Arkansas Epilepsy Program found treatment with ... compared with placebo, for patients with uncontrolled partial-onset seizures ... in Epilepsia , a journal published by Wiley-Blackwell ... Epilepsy affects up to 2% of the worldwide ...
... papillomavirus (HPV) DNA-based testing or visual inspection of the ... had a statistically significant reduction in high grade cervical ... according to a study published online Sept. 30 in ... In many developing countries, especially in ...
... of Health scientists could explain how Salmonella bacteria, a ... In a study published this week in the ... describe finding a reservoir of rapidly replicating Salmonella inside ... cells and are pushed from the epithelial layer by ...
... MEDFORD/SOMERVILLE, Mass.--Researchers from Tufts University School of Engineering and ... precursors to the potent anti-cancer compound Taxol in an ... The findings are significant steps on the way to ... to design new Taxol-like pharmaceuticals. The work ...
... Louisville School of Nursing has earned a $792,000 grant ... Health Resources and Services Administration to develop nursing informatics ... well as practicing nurses from University of Louisville Hospital. ... a tsunami of patient data in order to make ...
Cached Medicine News:Health News:New lung cancer research finds half of advanced lung cancer patients receive chemotherapy 2Health News:Adjunctive rufinamide reduces refractory partial-onset seizures 2Health News:HPV screen-and treat-intervention effective in cervical cancer prevention 2Health News:NIH scientists describe how salmonella bacteria spread in humans 2Health News:Researchers advance biosynthesis of potent anti-cancer drug Taxol 2Health News:UofL School of Nursing awarded grant to fund new informatics education project 2
... Testing System: The D-10 Hemoglobin Testing ... package. It provides a fully automated system ... into a single platform. Programs for rapid ... screen away and can be easily integrated ...
... 70 hematology system delivers a ... Designed for speed and accuracy, ... cost-effectiveness with impressive productivity. The ... on its own or twinned ...
Ac.T 5diff CP allows quick and direct access to a closed sample tubea feature that reduces manual sample handling, saves time and enhances safety by eliminating operators exposure to biohazards....
... The LH 755 simplifies and ... integrating expert automation and advanced ... delivers reliable, accurate results every ... best slide quality with its ...
Medicine Products: